Últimas noticias sobre HeartSciences (NASDAQ:HSCS) Bolsa

Heart Test Laboratories

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

HeartSciences Inc

Apple's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/04/44751387/apple-analyst-slashes-price-forecast-on-weak-iphone-demand-ai-revenue-despite-less-tariff-risk">biggest iPhone headache</a> might not be a chip shortage — it's tariffs. President Donald Trump's aggressive new round of China tariffs has temporarily spared electronics like smartphones and laptops, but that grace period is short-lived.&nbsp;
Commerce Secretary Howard Lutnick on Sunday told <a href="https://abcnews.go.com/Politics/commerce-secretary-lutnick-tariff-exemptions-electronics-temporary/story?id=120752319">ABC's "This Week"</a> that Apple and other tech companies should expect new semiconductor-specific tariffs "in probably a month or two."&nbsp;
Apple's dependence on China is massive. Roughly 90% of iPhones are made there. As <a href="https://www.theguardian.com/us-news/2025/apr/11/iphone-apple-trump-tariffs-tech-us-china">The Guardian reports</a>, if tariffs stick and Apple doesn't shift production, the iPhone 16 Pro Max could jump from $1,199 to $2,150 — <a href="https://www.benzinga.com/markets/equities/25/04/44728758/trumps-tariffs-could-push-apple-iphone-prices-to-a-staggering-3500-says-top-analyst">or even $3,500</a> if production were forced into the U.S.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Ironically, this was a debate 14 years ago.
At a 2011 Silicon Valley dinner with then-President Barack Obama, Apple CEO <a href="https://www.benzinga.com/personal-finance/25/04/44780772/bill-gates-said-its-a-gross-oversimplification-to-compare-elon-musk-to-genius-steve-jobs-you-wouldnt-walk-into-a-room-and-confu">Steve Jobs </a>gave a blunt answer when asked what it would take to make iPhones in America: "Those jobs aren't coming back." That quote, reported by <a href="https://www.nytimes.com/2012/01/22/business/apple-america-and-a-squeezed-middle-class.html">The New York Times</a>, captured the stark reality of globalized manufacturing.&nbsp;
It wasn't just about labor costs. At the time of the 2011 article, experts estimated that paying American wages would only add about $65 to each iPhone.
The real issue was China's supply chain dominance. "You need a million screws? That factory is a block away," a former Apple executive told the Times.
In that same dinner, Jobs said that Apple could potentially bring some high-skill manufacturing to the U.S. if the government helped train engineers. But he was clear: America didn't have the mid-level engineering workforce or production speed needed to compete.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Current Apple CEO Tim Cook has tried to soften that stance. Apple in Februay <a href="https://www.apple.com/newsroom/2025/02/apple-will-spend-more-than-500-billion-usd-in-the-us-over-the-next-four-years/">announced</a> plans to invest $500 billion in the U.S. over four years, building a new factory in Texas and expanding teams across 10 states. But most iPhones are still made abroad.
Even back in 2012, Cook pledged $100 million to build some Mac computers in the U.S. While this move garnered attention, analysts viewed it as a strategic decision rather than a significant shift in Apple's manufacturing strategy. Tom Dinges, a senior supply chain analyst at IHS, <a href="https://www.wired.com/2012/12/apple-insourcing/">told Wired</a> the impact would be minimal across Apple's global operations.
But more than a decade later, the conditions Cook once hedged against may be catching up.
Apple has started ramping up production in India, aiming for 25 million units this year, but China remains its manufacturing heart. As Trump pushes tariffs, Apple may be forced to test Jobs' theory — whether those jobs really are gone for good, or whether a $3,500 iPhone is what it takes to bring them home.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li>With shares starting at $1.52, <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">this could be your chance to invest in the future of healthcare</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

AAPL

Steve Jobs Said 14 Years Ago iPhones Would Never Be Made In The U.S.: 'Those Jobs Aren't Coming Back'—Now Tariffs Could Lift Price To $3,500

Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) has outperformed the market over the past 20 years by 2.48% on an annualized basis producing an average annual return of 10.38%. Currently, Micron Technology has a market capitalization of $77.11 billion. 
Buying $1000 In MU: If an investor had bought $1000 of MU stock 20 years ago, it would be worth $7,181.63 today based on a price of $69.00 for MU at the time of writing.
<h3>Micron Technology's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744929011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Micron Technology 20 Years Ago Would Be Worth This Much Today

Texas Pacific Land (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>) has outperformed the market over the past 10 years by 44.19% on an annualized basis producing an average annual return of 53.78%. Currently, Texas Pacific Land has a market capitalization of $29.85 billion. 
Buying $100 In TPL: If an investor had bought $100 of TPL stock 10 years ago, it would be worth $7,330.05 today based on a price of $1298.64 for TPL at the time of writing.
<h3>Texas Pacific Land's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744928110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Texas Pacific Land 10 Years Ago Would Be Worth This Much Today

Spring offers an ideal opportunity to refresh financial health. Just as decluttering a home brings clarity and calm, conducting a financial spring cleaning can help gain control, reduce stress and set the stage for future success. Here are key<a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44854372/gold-hits-new-record-highs-as-safe-haven-demand-climbs-2-ways-to-invest"> steps to consider:</a>
<h1 class="wp-block-heading">Review Budget and Spending</h1>
Begin by revisiting the household budget. Track expenses over recent months to reveal unnecessary or impulsive purchases and adjust the budget to align with current financial goals — such as saving for a vacation, paying down debt or building an emergency fund.&nbsp;
Credit Karma, an app from Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>), can organize each transaction by category and track spending habits and identify leftover funds available for investing or saving.&nbsp;
Read Next:<a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable"> UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;&nbsp;</a>
<h1 class="wp-block-heading">Tackle Debt Strategically</h1>
Addressing debt is an essential part of financial spring cleaning. Listing all debts, including interest rates and minimum payments, can help prioritize high-interest debts like credit cards. Paying off high-interest debt quickly helps save money and can enhance credit scores.
<h1 class="wp-block-heading">Optimize Savings</h1>
Evaluate savings accounts and emergency funds often, but at least once a year. Ideally, an emergency fund should cover three to six months of expenses or more. Automatic transfers to savings accounts can facilitate the steady growth of financial reserves.&nbsp;
Acorns offers<a href="https://www.acorns.com/"> an app </a>that can automatically transfer small amounts from a checking account into a savings account to build an emergency fund over time.&nbsp;
<h1 class="wp-block-heading">Check Subscriptions and Bills</h1>
Reviewing and canceling unused subscriptions, as well as negotiating bills such as cable, internet or insurance, can lead to significant monthly savings. The savings can then be redirected toward more important financial objectives.&nbsp;
Rocket Money, an app from Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), can help identify unused or duplicate subscriptions and even help to cancel them.&nbsp;
<h1 class="wp-block-heading">Plan for the Future</h1>
Review retirement accounts and investment portfolios to ensure that asset allocation matches risk tolerance and time horizons. For those who have yet to begin investing, spring presents an excellent opportunity to start.
Some online brokerages, like Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) and Webull Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>), offer retirement investment accounts and easy-to-learn apps.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/44817229/chinese-tiktok-influencers-expose-cheap-nike-lululemon-suppliers-to-bypass-trump-tariffs">Chinese TikTok Influencers &#8216;Expose&#8217; Cheap Nike, Lululemon Suppliers To Bypass Trump Tariffs&nbsp;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

BULL

HOOD

INTU

'Spring Clean' Your Personal Finances With These Apps

<a href="https://www.reuters.com/business/healthcare-pharmaceuticals/fda-fires-most-negotiators-pharma-user-fee-talks-sources-say-2025-04-17/">https://www.reuters.com/business/healthcare-pharmaceuticals/fda-fires-most-negotiators-pharma-user-fee-talks-sources-say-2025-04-17/</a>

Biotech

General

'FDA Fires Most Negotiators For Pharma User Fee Talks, Sources Say' - Reuters Exclusive

In the latest quarter, 10 analysts provided ratings for Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of $16.5, a high estimate of $29.00, and a low estimate of $11.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.79%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927268_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Myriad Genetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $14.00&#x7C;$18.00 &#x7C; 
&#x7C;Sung Ji Nam &#x7C;Scotiabank &#x7C;Lowers &#x7C;Sector Outperform&#x7C; $20.00&#x7C;$24.00 &#x7C; 
&#x7C;Dave Weiner &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $12.50&#x7C;$11.50 &#x7C; 
&#x7C;Dave Weiner &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $11.50&#x7C;$14.00 &#x7C; 
&#x7C;Derik De Bruin &#x7C;B of A Securities &#x7C;Lowers &#x7C;Underperform &#x7C; $11.00&#x7C;$13.00 &#x7C; 
&#x7C;Andrew Cooper &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $19.00&#x7C;$27.00 &#x7C; 
&#x7C;Lu Li &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $16.00&#x7C;$18.00 &#x7C; 
&#x7C;John Wilkin &#x7C;Craig-Hallum &#x7C;Announces &#x7C;Buy &#x7C; $29.00&#x7C;- &#x7C; 
&#x7C;John Peterson &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $14.00&#x7C;$24.00 &#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $18.00&#x7C;$29.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Myriad Genetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Myriad Genetics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Myriad Genetics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Myriad Genetics's Background</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Myriad Genetics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Myriad Genetics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.12%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Myriad Genetics's net margin excels beyond industry benchmarks, reaching -20.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Myriad Genetics's ROE excels beyond industry benchmarks, reaching -5.93%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.03%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.2, Myriad Genetics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MYGN

Demystifying Myriad Genetics: Insights From 10 Analyst Reviews

8 analysts have shared their evaluations of Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Astera Labs and provided 12-month price targets. The average target is $115.38, accompanied by a high estimate of $142.00 and a low estimate of $82.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 12.12%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927261_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Astera Labs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-------------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Tore Svanberg &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $100.00&#x7C;$150.00 &#x7C; 
&#x7C;Atif Malik &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $100.00&#x7C;$120.00 &#x7C; 
&#x7C;Srini Pajjuri &#x7C;Raymond James &#x7C;Announces &#x7C;Outperform &#x7C; $82.00&#x7C;- &#x7C; 
&#x7C;Richard Shannon &#x7C;Craig-Hallum &#x7C;Raises &#x7C;Buy &#x7C; $125.00&#x7C;$105.00 &#x7C; 
&#x7C;Quinn Bolton &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $140.00&#x7C;$140.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $114.00&#x7C;$142.00 &#x7C; 
&#x7C;Gus Richard &#x7C;Northland Capital Markets&#x7C;Maintains &#x7C;Outperform &#x7C; $120.00&#x7C;$120.00 &#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $142.00&#x7C;$142.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Astera Labs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Astera Labs compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Astera Labs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Astera Labs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Astera Labs analyst ratings.</a>
<h2>Delving into Astera Labs's Background</h2>
Astera Labs Inc designs and delivers semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform integrates semiconductor technology, microcontrollers, sensors, and software to enhance performance, scalability, and data management. The company offers products such as integrated circuits (ICs), boards, and modules, catering to hyperscalers and system OEMs. The company's solutions focus on data, network, and memory management in AI-driven platforms.
<h3>Financial Milestones: Astera Labs's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Astera Labs's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 179.32%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Astera Labs's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 17.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Astera Labs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.67%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Astera Labs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 2.43%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Astera Labs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALAB

8 Analysts Have This To Say About Astera Labs

In the preceding three months, 8 analysts have released ratings for C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for C3.ai, revealing an average target of $23.62, a high estimate of $30.00, and a low estimate of $17.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 27.05%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927251_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive C3.ai. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Eric Heath &#x7C;Keybanc &#x7C;Lowers &#x7C;Underweight &#x7C; $17.00&#x7C;$21.00 &#x7C; 
&#x7C;Sanjit Singh &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $20.00&#x7C;$30.00 &#x7C; 
&#x7C;Gil Luria &#x7C;DA Davidson &#x7C;Lowers &#x7C;Neutral &#x7C; $18.00&#x7C;$25.00 &#x7C; 
&#x7C;Kingsley Crane &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $30.00&#x7C;$40.00 &#x7C; 
&#x7C;Gil Luria &#x7C;DA Davidson &#x7C;Lowers &#x7C;Neutral &#x7C; $25.00&#x7C;$40.00 &#x7C; 
&#x7C;John Vinh &#x7C;Keybanc &#x7C;Lowers &#x7C;Underweight &#x7C; $21.00&#x7C;$29.00 &#x7C; 
&#x7C;Sanjit Singh &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $30.00&#x7C;$32.00 &#x7C; 
&#x7C;Arvind Ramnani &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $28.00&#x7C;$42.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to C3.ai. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of C3.ai compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of C3.ai's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on C3.ai analyst ratings.</a>
<h2>Discovering C3.ai: A Closer Look</h2>
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
<h3>Unraveling the Financial Story of C3.ai</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: C3.ai's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 26.0%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: C3.ai's net margin excels beyond industry benchmarks, reaching -81.19%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): C3.ai's ROE stands out, surpassing industry averages. With an impressive ROE of -9.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): C3.ai's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.63%, the company may face hurdles in achieving optimal financial performance.
Debt Management: C3.ai's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying C3.ai: Insights From 8 Analyst Reviews

10 analysts have shared their evaluations of Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Welltower and provided 12-month price targets. The average target is $173.6, accompanied by a high estimate of $242.00 and a low estimate of $144.00. Observing a 9.18% increase, the current average has risen from the previous average price target of $159.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927239_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Welltower. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;John Kilichowski &#x7C;Wells Fargo &#x7C;Maintains &#x7C;Overweight &#x7C; $158.00&#x7C;$158.00 &#x7C; 
&#x7C;Omotayo Okusanya &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $170.00&#x7C;$141.00 &#x7C; 
&#x7C;John Kilichowski &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $158.00&#x7C;$140.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $166.00&#x7C;$165.00 &#x7C; 
&#x7C;Steve Sakwa &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;In-Line &#x7C; $145.00&#x7C;$144.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $165.00&#x7C;$144.00 &#x7C; 
&#x7C;Joshua Dennerlein &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $242.00&#x7C;$221.00 &#x7C; 
&#x7C;Richard Anderson &#x7C;Wedbush &#x7C;Raises &#x7C;Outperform &#x7C; $167.00&#x7C;$145.00 &#x7C; 
&#x7C;Nicholas Yulico &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $144.00&#x7C;$142.00 &#x7C; 
&#x7C;Joshua Dennerlein &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $221.00&#x7C;$190.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Welltower. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Welltower compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Welltower's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Welltower's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WELL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Welltower analyst ratings.</a>
<h2>Get to Know Welltower Better</h2>
Welltower owns a diversified healthcare portfolio of 2,271 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in both Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.
<h3>Financial Milestones: Welltower's Journey</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Welltower displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 29.18%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Welltower's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.41%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.39%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Welltower's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.24%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.52.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WELL

Breaking Down Welltower: 10 Analysts Share Their Views

19 analysts have expressed a variety of opinions on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Exelixis, presenting an average target of $37.74, a high estimate of $45.00, and a low estimate of $29.00. Observing a 3.91% increase, the current average has risen from the previous average price target of $36.32. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927228_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Exelixis is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $40.00&#x7C;$38.00 &#x7C; 
&#x7C;Derek Archila &#x7C;Wells Fargo &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $36.00&#x7C;$36.00 &#x7C; 
&#x7C;Peter Lawson &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$25.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;David Lebowitz &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $45.00&#x7C;$38.00 &#x7C; 
&#x7C;Michael Schmidt &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $42.00&#x7C;$42.00 &#x7C; 
&#x7C;Sudan Loganathan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$29.00 &#x7C; 
&#x7C;Stephen Willey &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $36.00&#x7C;$30.00 &#x7C; 
&#x7C;Joseph Catanzaro &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $38.00&#x7C;$37.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $34.00&#x7C;$30.00 &#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C; 
&#x7C;Asthika Goonewardene&#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $43.00&#x7C;$42.00 &#x7C; 
&#x7C;Sudan Loganathan &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $29.00&#x7C;$29.00 &#x7C; 
&#x7C;Robert Burns &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Jefferson Harralson &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $40.00&#x7C;$30.00 &#x7C; 
&#x7C;Jay Olson &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Perform &#x7C; $33.00&#x7C;$41.00 &#x7C; 
&#x7C;Silvan Tuerkcan &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $41.00&#x7C;$41.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exelixis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exelixis's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Exelixis's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exelixis analyst ratings.</a>
<h2>All You Need to Know About Exelixis</h2>
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Exelixis's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Exelixis showcased positive performance, achieving a revenue growth rate of 18.16% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exelixis's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 24.68%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 6.19%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exelixis's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: Exelixis's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXEL

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts

In the current market session, Mr. Cooper Gr Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) stock price is at $111.21, after a 1.34% drop. However, over the past month, the company's stock spiked by 5.32%, and in the past year, by 43.40%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744927219_0.png" alt="Past Year Chart" />

<h3>Mr. Cooper Gr P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Mr. Cooper Gr has a lower P/E than the aggregate P/E of 14.0 of the Financial Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744927219_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

COOP

P/E Ratio Insights for Mr. Cooper Gr

Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) has outperformed the market over the past 5 years by 20.12% on an annualized basis producing an average annual return of 34.15%. Currently, Liberty Energy has a market capitalization of $1.96 billion. 
Buying $1000 In LBRT: If an investor had bought $1000 of LBRT stock 5 years ago, it would be worth $4,209.06 today based on a price of $12.08 for LBRT at the time of writing.
<h3>Liberty Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744927219_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LBRT

Here's How Much $1000 Invested In Liberty Energy 5 Years Ago Would Be Worth Today

Reynolds Consumer Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REYN#NASDAQ">REYN</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.33, along with a high estimate of $32.00 and a low estimate of $24.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.59%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744927217_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Reynolds Consumer Prods is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Peter Grom &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $26.00&#x7C;$29.00 &#x7C; 
&#x7C;Andrea Teixeira &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $24.00&#x7C;$26.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $27.00&#x7C;$31.00 &#x7C; 
&#x7C;Brian McNamara &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $30.00&#x7C;$31.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $30.00&#x7C;$32.00 &#x7C; 
&#x7C;Mark Astrachan &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $31.00&#x7C;$32.00 &#x7C; 
&#x7C;Robert Ottenstein &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;Outperform &#x7C; $30.00&#x7C;$33.00 &#x7C; 
&#x7C;Lauren Lieberman &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $25.00&#x7C;$27.00 &#x7C; 
&#x7C;Nik Modi &#x7C;RBC Capital &#x7C;Maintains &#x7C;Sector Perform &#x7C; $32.00&#x7C;$32.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reynolds Consumer Prods. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Reynolds Consumer Prods compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Reynolds Consumer Prods's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Reynolds Consumer Prods's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/REYN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Reynolds Consumer Prods analyst ratings.</a>
<h2>Delving into Reynolds Consumer Prods's Background</h2>
Reynolds Consumer Products Inc is a provider of household products. The firm is engaged in the production and sales of cooking products, waste and storage products, and tableware. It operates through four reportable segments namely, Reynolds Cooking and Baking, Hefty Waste and Storage, Hefty Tableware, and Presto Products. Reynolds Cooking and Baking segment produce branded and store brand aluminum foil, disposable aluminum pans, parchment paper, freezer paper, wax paper, butcher paper, plastic wrap, baking cups, oven bags and slow cooker liners.
<h3>Reynolds Consumer Prods's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Reynolds Consumer Prods showcased positive performance, achieving a revenue growth rate of 1.39% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 11.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Reynolds Consumer Prods's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.75%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.49%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Reynolds Consumer Prods's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.83.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

REYN

Assessing Reynolds Consumer Prods: Insights From 9 Financial Analysts

When Chinese AI lab Deepseek released a state-of-the-art large language model for free, it marked a turning point in enterprise AI strategy — especially for financial institutions. The move underscored a broader shift: the emergence of open-source AI as a serious contender to proprietary offerings.
While open-source tools have long been foundational to developer ecosystems, their influence rarely extended into core infrastructure. That changed when companies like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) began publishing foundational models freely, echoing Google's Android strategy — build the ecosystem now, monetize later.
The trend is accelerating. Deepseek's release made waves for several reasons:
<ul>
<li>State-of-the-art models are now widely available at no cost.</li>
<li>Training these models has become more economically feasible.</li>
<li>Open-source distribution can accelerate adoption — Deepseek's app reportedly reached the top of mobile app store rankings within days of launch.</li>
</ul>
These developments open the door for enterprises — including banks — to stop merely consuming AI and start building it.
<h1 class="wp-block-heading">Banking's Quiet AI Revolution</h1>
<a href="https://www.citigroup.com/global/news/press-release/2024/citi-publishes-new-report-ai-in-finance">According to a 2024 Citibank report</a>, up to 54% of banking roles could be impacted by AI. The sector's heavy reliance on manual workflows, compliance-heavy documentation and repetitive research makes it ripe for disruption.
So far, most large U.S. banks have opted to explore generative AI via partnerships rather than by developing their own infrastructure:
<ul>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) has deployed tools for automating meeting notes and summarizing research, aimed at enhancing financial advisor productivity.</li>
<li>JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) partnered with OpenAI to launch internal assistants for email and document drafting, all integrated into its secure Omni platform.</li>
<li>Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) built an internal hub to access specialized AI tools, with a focus on developer productivity and task-specific model optimization.</li>
<li>Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) and Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) are focused on customer-facing AI, deploying chatbots in mobile banking apps to answer user queries and handle support.</li>
</ul>
<h1 class="wp-block-heading">Why Banks May Need to Build Their Own AI</h1>
With open-source AI infrastructure advancing rapidly, banks now have compelling reasons to develop internal models:
<h3 class="wp-block-heading">&#x1f510; Enhanced Data Security</h3>
By building proprietary LLMs, banks can maintain end-to-end control over sensitive data, reduce reliance on external vendors, and ensure compliance with strict regulatory requirements.
<h3 class="wp-block-heading">&#x1f4ca; Unlocking Proprietary Data Value</h3>
Banks are sitting on massive pools of transaction and behavioral data that could power competitive AI models. Training open-source models in-house offers a cost-effective way to turn this underutilized data into differentiated digital services.
<h3 class="wp-block-heading">&#x1f4b8; Monetization Potential</h3>
Custom bank-built AI can serve internal teams or be licensed externally. As demand rises for financial data integration, models trained on proprietary datasets could enable entirely new product lines or revenue channels.
<h1 class="wp-block-heading">The Strategic Fork in the Road</h1>
Banks are now faced with a strategic decision: continue outsourcing AI capabilities to tech firms — or invest in building their own. With massive IT budgets and uniquely rich data troves, financial institutions are well-positioned to become creators of infrastructure, not just users.
The road ahead is clear. As open-source AI evolves, banking giants that invest in their own models today may define the next era of financial services.
Read Next: •<a href="https://www.benzinga.com/25/04/44838028/us-bancorp-beats-q1-estimates-on-strength-in-noninterest-income-loan-growth-and-cost-discipline"> U.S. Bancorp Beats Q1 Estimates, CEO Says &#8216;Revenues Outpaced Expenses&#8217;</a> Photo: Shutterstock

Tech

BankGPT: Why Open-Source AI May Reshape Future Of Financial Services

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 19.34% on an annualized basis producing an average annual return of 33.37%. Currently, Natera has a market capitalization of $20.02 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $423.33 today based on a price of $148.08 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744926311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTRA

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today

Enterprise Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBTC#NASDAQ">EBTC</a>) reported quarterly earnings of $0.84 per share. This is a 21.74 percent increase over earnings of $0.69 per share from the same period last year.

Earnings

EBTC

Enterprise Bancorp Q1 EPS $0.84 Up From $0.69 YoY

WKEY

WISeKey FY24 EPS $(0.39) Up From $(0.51) YoY; Revenue $11.875M Down From $30.918M YoY

BV Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVFL#NASDAQ">BVFL</a>) reported quarterly earnings of $0.21 per share. This is a 12.5 percent decrease over earnings of $0.24 per share from the same period last year.

BVFL

BV Financial Q1 EPS $0.21 Down From $0.24 YoY

United Security (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBFO#NASDAQ">UBFO</a>) reported quarterly earnings of $0.16 per share. This is a 33.33 percent decrease over earnings of $0.24 per share from the same period last year. The company reported $13.66 million in sales this quarter. This is a 6.96 percent increase over sales of $12.77 million the same period last year.

UBFO

United Security Q1 EPS $0.16 Down From $0.24 YoY, Sales $13.66M Up From $12.77M YoY

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 2.96% on an annualized basis producing an average annual return of 12.55%. Currently, Danaher has a market capitalization of $133.67 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $326.41 today based on a price of $186.83 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744925426_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

HeartSciences

Noticias

Últimas noticias sobre HeartSciences (NASDAQ:HSCS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL